3 results
Approved WMOWill not start
Phase 2: To evaluate progression-free survival (PFS) as the primary efficacy measure of MLN1117 plus docetaxel versus docetaxel alone in patients with advanced NSCLC
Approved WMOCompleted
Primary: To compare the reduction in frequency of partial-onset seizures on each of two trough ranges of everolimus (3-7 ng/mL and 9-15 ng/mL) versus placebo in patients with TSC who are taking one to three AEDs. Key secondary: Ability to completely…
Approved WMOCompleted
To determine whether a potent topical CS is more effective than a mild topical CS in the treatment of children with a moderate flare-up of atopic dermatitis in primary care on short and long term.